Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatme

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease is a phase 2 interventional study registered as NCT06607458 by Delcath Systems Inc., with 90 participants planned, started 2025-08-05 and due to reach its primary completion in 2026-12. Interventions recorded: Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone. Conditions listed: Refractory Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.